Recombinant human hepatocyte growth factor (HGF), but not rat HGF, elicits glomerular injury and albuminuria in normal rats via an immune complex-dependent mechanism

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 3, 2011, Pages 192-201

  Mizuno, Shinya ^a   Ikebuchi, Fumie ^b   Fukuta, Kazuhiro ^b,c   Kato, Takashi ^a,c   Matsumoto, Kunio ^a,d   Adachi, Kiichi ^b,c   Abe, Tetsushi ^b   Nakamura, Toshikazu ^a,c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Saito Laboratory   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Albuminuria; Glomerulonephritis; Hepatocyte growth factor; IgG deposition; Immune complex; Mesangial cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 4; DODECYL SULFATE SODIUM; IMMUNOGLOBULIN G; RECOMBINANT SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA; ANTIGEN ANTIBODY COMPLEX; HGF PROTEIN, HUMAN; RECOMBINANT PROTEIN; SCATTER FACTOR;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGENICITY; ARTICLE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; GLOMERULAR DYSFUNCTION; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY HYPERTROPHY; LOW DRUG DOSE; MACROPHAGE; MESANGIUM CELL; NONHUMAN; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RAT; UPREGULATION; URINALYSIS; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; HYPERTROPHY; KIDNEY DISEASES; MESANGIUM; METABOLISM;

ALBUMINURIA; ANIMALS; ANTIGEN-ANTIBODY COMPLEX; GLOMERULAR MESANGIUM; HEPATOCYTE GROWTH FACTOR; HUMANS; HYPERTROPHY; IMMUNOGLOBULIN G; KIDNEY DISEASES; RATS; RECOMBINANT PROTEINS;

EID: 79952022043     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05483.x     Document Type: Article

References (50)

1. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol. Rev. 2008; 88: 451-87.
2. Eddy A. Role of cellular infiltrates in response to proteinuria. Am. J. Kidney Dis. 2001; 37 (Suppl.): S25-9.
3. Sarafidis PA. Proteinuria: Natural course, prognostic implications and therapeutic considerations. Minerva Med. 2007; 98: 693-711.
4. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 1984; 122: 1450-9.
5. Nakamura T, Nishizawa T, Hagiya M et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3.
6. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 2010; 86: 588-610.
7. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc. Natl Acad. Sci. USA 1994; 91: 4357-61.
8. Matsumoto K, Nakamura T. Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases. Kidney Int. 2001; 59: 2023-38.
9. Fornoni A, Li H, Foschi A, Striker GE, Striker LJ. Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis. Am. J. Pathol. 2001; 158: 275-80.
10. Yo Y, Morishita R, Nakamura S et al. Potential role of hepatocyte growth factor in the maintenance of renal structure. Anti-apoptotic action of HGF on epithelial cells. Kidney Int. 1998; 54: 1128-38.
11. Mizuno S, Kurosawa T, Matsumoto K, Mizuno-Horikawa Y, Okamoto M, Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J. Clin. Invest. 1998; 101: 1827-34.
12. Mizuno S, Nakamura T. Suppressions of chronic glomerular injuries and TGF-β1 production by HGF in attenuation of murine diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2004; 286: F134-43.
13. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J. Am. Soc. Nephrol. 2004; 15: 2868-81.
14. Takayama H, LaRochelle WJ, Sabnis SG, Otsuka T, Merlino G. Renal tubular hyperplasia, polycystic disease, and glomerulosclerosis in transgenic mice overexpressing hepatocyte growth factor/scatter factor. Lab. Invest. 1997; 77: 131-8.
15. Kusumoto K, Ido A, Moriuchi A et al. Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats. Int. J. Mol. Med. 2006; 17: 503-9.
16. Takano Y, Yamauchi K, Hiramatsu N et al. Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am. J. Physiol. Renal Physiol. 2007; 292: F1573-82.
17. Iskandar SS, Jennette JC. Interaction of antigen load and antibody response in determining heterologous protein nephritogenicity in inbred mice. Lab. Invest. 1983; 48: 726-34.
18. Tashiro K, Hagiya M, Nishizawa T et al. Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues. Proc. Natl Acad. Sci. USA 1990; 87: 3200-4.
19. Kato T, Kurosawa TM, Taketo MM. The possible involvement of tensin2 in the expression and extension of nephrin by glomerular podocytes in mice. Biomed. Res. 2008; 29: 279-87.
20. Yamada A, Mizuno S, Iwanari H et al. Rapid and sensitive enzyme-linked immunosorbent assay for measurement of HGF in rat and human tissues. Biomed. Res. 1995; 16: 105-14.
21. López-Armada MJ, Gómez-Guerrero C, Egido J. Receptors for immune complexes activate gene expression and synthesis of matrix proteins in cultured rat and human mesangial cells: Role of TGF-β. J. Immunol. 1996; 157: 2136-42.
22. Uematsu Y, Fujise N, Kohsaka K, Masunaga H, Higashio K. Effective administration route for the deleted form of hepatocyte growth factor to exert its pharmacological effects. J. Pharm. Sci. 1999; 88: 131-5.
23. Couser WG. Mechanisms of glomerular injury in immune-complex disease. Kidney Int. 1985; 28: 569-83.
24. Mauer SM, Fish AJ, Day NK, Michael AF. The glomerular mesangium. II. Studies of macromolecular uptake in nephrotoxic nephritis in rats. J. Clin. Invest. 1974; 53: 431-9.
25. Timmerman JJ, Van Gijlswijk-Janssen DJ, Van Der Kooij SW, Van Es LA, Daha MR. Antigen-antibody complexes enhance the production of complement component C3 by human mesangial cells. J. Am. Soc. Nephrol. 1997; 8: 1257-65.
26. Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J. Am. Soc. Nephrol. 2004; 15: 2637-47.
27. Cruzado JM, Lloberas N, Torras J et al. Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 2004; 53: 1119-27.
28. Mori T, Shimizu A, Masuda Y, Fukuda Y, Yamanaka N. Hepatocyte growth factor-stimulating endothelial cell growth and accelerating glomerular capillary repair in experimental progressive glomerulonephritis. Nephron Exp. Nephrol. 2003; 94: E44-54.
29. Liu Y. Hepatocyte growth factor in kidney fibrosis. Therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. 2004; 287: F7-16.
30. Mizuno S, Matsumoto K, Nakamura T. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front. Biosci. 2008; 13: 7072-86.
31. Nakanishi C, Moriuchi A, Ido A et al. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient 1-amino acid-defined diet. Oncol. Rep. 2006; 16: 25-31.
32. Noble B, Steward MW, Vladutiu A, Brentjens JR. Relationship of the quality and quantity of circulating anti-BSA antibodies to the severity of glomerulonephritis in rats with chronic serum sickness. Clin. Exp. Immunol. 1987; 67: 277-82.
33. Hora K, Satriano JA, Santiago A et al. Receptors for IgG complexes activate synthesis of monocyte chemoattractant peptide 1 and colony-stimulating factor 1. Proc. Natl Acad. Sci. USA 1992; 89: 1745-9.
34. Gómez-Guerrero C, Duque N, Casado MT et al. Administration of IgG Fc fragments prevents glomerular injury in experimental immune complex nephritis. J. Immunol. 2000; 164: 2092-101.
35. Bessho K, Mizuno S, Matsumoto K, Nakamura T. Counteractive effects of HGF on PDGF-induced mesangial cell proliferation in a rat model of glomerulonephritis. Am. J. Physiol. Renal Physiol. 2003; 284: F1171-80.
36. Wada T, Yokoyama H, Furuichi K et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J. 1996; 10: 1418-25.
37. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. 1993; 92: 2597-601.
38. Singhal PC, Santiago A, Satriano J, Hays RM, Schlondorff D. Effects of vasoactive agents on uptake of immunoglobulin G complexes by mesangial cells. Am. J. Physiol. 1990; 258: F589-96.
39. Ketteler M, Noble NA, Border WA. Transforming growth factor-β and angiotensin II. The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu. Rev. Physiol. 1995; 57: 279-95.
40. Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am. J. Pathol. 2008; 172: 299-308.
41. Iida H, Seifert R, Alpers CE et al. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc. Natl Acad. Sci. USA 1991; 88: 6560-4.
42. Braun M, Davis AE. Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int. 1998; 54: 1542-9.
43. Couser WG, Pippin JW, Shankland SJ. Complement (C5b-9) induces DNA synthesis in rat mesangial cells in vitro. Kidney Int. 2001; 59: 905-12.
44. Gao L, Qiu W, Wang Y, Xu W, Xu J, Tong J. Sublytic complement C5b-9 complexes induce thrombospondin-1 production in rat glomerular mesangial cells via PI3-k/Akt: Association with activation of latent transforming growth factor-beta1. Clin. Exp. Immunol. 2006; 144: 326-34.
45. Noble B, Milgrom M, Van Liew JB, Brentjens JR. Chronic serum sickness in the rat: Influence of antigen dose, route of antigen administration and strain of rat on the development of disease. Clin. Exp. Immunol. 1981; 46: 499-507.
46. Inoue T, Okada H, Kobayashi T et al. Hepatocyte growth factor counteracts transforming growth factor-β1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6-nephrectomized mice. FASEB J. 2003; 17: 268-70.
47. Masunaga H, Fujise N, Shiota A et al. Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries. Eur. J. Pharmacol. 1998; 342: 267-79.
48. Li H, Jiang T, Lin Y, Zhao Z, Zhang N. HGF protects rat mesangial cells from high glucose-mediated oxidative stress. Am. J. Nephrol. 2006; 26: 519-30.
49. Wen X, Li Y, Hu K, Dai C, Liu Y. Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am. J. Pathol. 2005; 167: 947-57.
50. Kato T, Mizuno S, Nakamura T Preservations of nephrin and synaptopodin by HGF in podocytes for the attenuations of foot process injury and albuminuria in nephritic mice. Nephrology 2011; (in press).